Rare diseases
Investigational molecules
Locations
147 conditions with trials, the busiest first
548 trials across Europe, recruiting first
Study of MK-2214 to slow disease progression in people with early Alzheimer's disease
BelgiumStudy of NBI-1065845 as add-on treatment to prevent depression relapse in adults with Major Depressive Disorder who responded to initial treatment
BulgariaStudy of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer's Disease
FranceStudy of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks
CzechiaLong-term safety and effectiveness study of CYB003 (deupsilocin besilate) with optional additional doses for people with Major Depressive Disorder
CzechiaStudy of Flumazenil to Reduce Side Effects of Electroconvulsive Therapy in Patients with Depression
DenmarkStudy on Daridorexant for Treating Bedwetting in Adolescents
DenmarkEvaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy
BelgiumAssessment of NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder
BulgariaStudy of Long-Term Neurocognitive Outcomes in Children with Phenylketonuria Treated with Sepiapterin
FranceStudy on the Effectiveness and Safety of NBI-1065845 for Adults with Major Depressive Disorder
CroatiaStudy on the Effects of Psilocybin for Young Adults with Anorexia Nervosa
SwedenThe therapies tested most often in Psychiatric disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
